Investing in the Future of Precision Cancer Medicine

Developing a first-in-class, 3rd generation Polo-like Kinase 1 (PLK1) Inhibitor to treat leukemias, lymphomas
and solid tumor cancers

Press Releases

Archives: Search / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

Apr 23, 2019
Data provides support for clinical evaluation of onvansertib in combination with venetoclax in patients with difficult-to-treat relapsed or refractory acute myeloid leukemia (AML)
Apr 5, 2019
Complete response achieved in 3 of 6 (50%) evaluable patients at the highest doses (27mg/m2 and 40mg/m2) of onvansertib in combination with standard-of-care decitabine
Apr 5, 2019
Investment follows recent receipt of ~$3.2 million from exercise of previously issued warrants
Apr 2, 2019
Early PSA response observed when onvansertib is added to abiraterone (Zytiga®) in 2 of 6 patients to-date; first patient achieves primary efficacy endpoint
Apr 1, 2019
Greatest anti-leukemic activity has been observed in the onvansertib + decitabine arm, with complete response in 2 of 4 (50%) of evaluable patients from the two highest dose levels